Should Value Investors Buy Popular (BPOP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Verizon: Boosting 'Income' With Options Writing On This Popular High Yielder
Verizon offers a high, near-7% yield and trades at a discounted ~8.5x P/E, below its historical average. I maintain a core long position in VZ, supplementing income with an options wheel strategy to enhance returns. Recent CEO transition raised dividend concerns, but management reiterated a strong commitment to sustaining shareholder returns and disciplined capital allocation.
An Important Warning: Popular Income Stocks Are Getting Risky Here
Leading blue-chip dividend growth stocks appear to be untouchable, until you zoom out and see what's changed. A small shift in the macro could turn today's favorites into tomorrow's regrets. I detail why I'm walking away before most investors even notice the risk.
Why Popular (BPOP) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Popular (BPOP) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Eli Lilly (LLY) said Monday that it's lowering the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower drug costs.
Eli Lilly Stock in Focus After Slashing Cost of Popular Drug
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound.
Are Investors Undervaluing Popular (BPOP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Does Popular (BPOP) Have the Potential to Rally 26.8% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Popular (BPOP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Popular (BPOP) Upgraded to Strong Buy: Here's Why
Popular (BPOP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Value Stock to Buy for Nov. 17th
SKYW, FMBH and BPOP made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 17, 2025.
Best Income Stocks to Buy for Nov. 17th
TRTX, PFBC and BPOP made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 17, 2025.
